Literature DB >> 9675465

Prechallenge antibodies moderate disease expression in adults experimentally exposed to rhinovirus strain hanks.

C M Alper1, W J Doyle, D P Skoner, C A Buchman, S Cohen, J M Gwaltney.   

Abstract

This double-blind study determined the influence of serum neutralizing antibody titers on the rate of infection and magnitude of disease expression after experimental exposure of adult volunteers to rhinovirus strain Hanks (RV-H). A total of 133 healthy volunteers were tested for antibody status, cloistered for a 6-day period, and challenged with RV-H at the end of the first cloister day. On these days, response to viral challenge is assessed with symptom diaries and physical examinations. The low-titer infected group was significantly different from the intermediate-titer infected and the uninfected groups in terms of postchallenge nasal and throat symptoms, expelled secretion weights, nasal mucociliary clearance rates, and frequency of negative middle ear pressures. A similar trend held for the infected high-titer vs. low-titer group comparisons. These data show that high homotypic serum neutralizing antibody titers are associated with protection from infection and lessened signs and symptoms following experimental RV-H exposure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675465     DOI: 10.1086/514634

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

Review 1.  Human rhinoviruses.

Authors:  Samantha E Jacobs; Daryl M Lamson; Kirsten St George; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

Review 2.  Understanding the Association of Human Rhinovirus with Asthma.

Authors:  Cosby A Stone; E Kathryn Miller
Journal:  Clin Vaccine Immunol       Date:  2015-09-16

3.  Circulating Memory CD4+ T Cells Target Conserved Epitopes of Rhinovirus Capsid Proteins and Respond Rapidly to Experimental Infection in Humans.

Authors:  Lyndsey M Muehling; Duy T Mai; William W Kwok; Peter W Heymann; Anna Pomés; Judith A Woodfolk
Journal:  J Immunol       Date:  2016-09-02       Impact factor: 5.422

Review 4.  Pathogenesis of rhinovirus infection.

Authors:  Joshua L Kennedy; Ronald B Turner; Thomas Braciale; Peter W Heymann; Larry Borish
Journal:  Curr Opin Virol       Date:  2012-04-27       Impact factor: 7.090

Review 5.  Viral rhinitis.

Authors:  D A Gentile; D P Skoner
Journal:  Curr Allergy Asthma Rep       Date:  2001-05       Impact factor: 4.806

Review 6.  Rhinovirus and asthma: a storied history of incompatibility.

Authors:  Catherine Hammond; Megan Kurten; Joshua L Kennedy
Journal:  Curr Allergy Asthma Rep       Date:  2015-02       Impact factor: 4.806

Review 7.  Viral otitis media.

Authors:  Craig A Buchman; George M Brinson
Journal:  Curr Allergy Asthma Rep       Date:  2003-07       Impact factor: 4.806

Review 8.  Rhinoviruses in the pathogenesis of asthma.

Authors:  Nikolaos G Papadopoulos; Stelios Psarras
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

9.  Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein.

Authors:  Nicholas Glanville; Gary R McLean; Bruno Guy; Valerie Lecouturier; Catherine Berry; Yves Girerd; Christophe Gregoire; Ross P Walton; Rebecca M Pearson; Tatiana Kebadze; Nicolas Burdin; Nathan W Bartlett; Jeffrey W Almond; Sebastian L Johnston
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

10.  Reduced rhinovirus-specific antibodies are associated with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalisation.

Authors:  Stephanie T Yerkovich; Belinda J Hales; Melanie L Carroll; Julie G Burel; Michelle A Towers; Daniel J Smith; Wayne R Thomas; John W Upham
Journal:  BMC Pulm Med       Date:  2012-07-31       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.